Lv3
226 积分 2023-08-03 加入
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
8小时前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
9小时前
已完结
Visual predictive check of longitudinal models and dropout
1个月前
已完结
Examining P-gp efflux kinetics guided by the BDDCS – Rational selection of in vitro assay designs and mathematical models
1个月前
已完结
Population Pharmacokinetics of Sotorasib in Healthy Subjects and Advanced Solid Tumor Patients Harboring a KRASG12C Mutation from Phase 1 and Phase 2 Studies
3个月前
已完结
Prediction of human drug clearance from animal data: Application of the rule of exponents and ‘fu corrected intercept method’ (FCIM)
5个月前
已完结
Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations
5个月前
已完结
Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics - a Minireview
5个月前
已完结
Application of Model‐Informed Drug Development in Dose Selection and Optimization for siRNA Therapies
5个月前
已完结
Endpoint Exposure‐Response Analyses in the Presence of Concurrent Dose Modification During Clinical Trials
5个月前
已完结
皖公网安备34019202002308
